Soligenix up on positive results from compatibility study of cancer therapy
04/05/2023 13:58
** Shares of Soligenix Inc SNGX.O more than triple to $5.4
premarket - biggest pct gainer across U.S. stock exchanges
** Drug developer said late-stage study evaluating its
light-based cancer therapy, HyBryte, showed it was suitable for
use in combination with any device capable of producing visible
light of an appropriate and consistent wavelength
** HyBryte is a topical ointment which is applied on lesions
and activated with the help of visible light
** Results also show therapy responded against cancerous
lesions in patients with a rare type of blood cancer, and showed
improvement in overall score on a index to assess lesion
severity
** SNGX's therapy is intended to treat cutaneous T-cell
lymphoma, a rare type of cancer that starts in certain white
blood cells and can cause redness or scaly patches on the skin
** As of last close, stock had fallen ~79% YTD
(Reporting by Khushi Mandowara in Bengaluru)
((Khushi.Mandowara@thomsonreuters.com;))